Abstract
PURPOSE: For lung transplant recipients (LTR), preservation of graft function and survival depends on immunosuppression regimens that usually include tacrolimus. Driven by lower incidences of nephrotoxicity, neurotoxicity and anaphylaxis, oral dosing of tacrolimus is favored over intravenous administration. Therefore, delivering tacrolimus to patients suffering from conditions that preclude oral dosing including malabsorption, gastroparesis, or being intubated presents challenges. Anecdotally, dosing tacrolimus sublingually has been used as an alternative to intravenous delivery. We aimed to determine the appropriate dose conversion of oral to sublingual tacrolimus that would achieve similar therapeutic blood levels in LTR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
